Given the convincing role of IL-6 in COVID-19 pathology, neutralization of the IL-6/IL-6r via Tocilizumab (a recombinant humanized anti-IL-6 receptor (IL-6r) monoclonal antibody (mAb), Sarilumab (a recombinant humanized anti-IL6r) and Siltuximab (a recombinant human-mouse chimeric monoclonal antibody that binds IL-6) may attenuate CS [127,128] and also prevent renal function impairment [129]. Here, IL6 is linked to COVID-19.